‘Spectacular’ accomplishments in multiple myeloma have led to a shift in patient outcomes
Within the past 2 decades, multiple myeloma has shifted from a highly lethal diagnosis to a condition that will no longer shorten the lifespan for many patients.
Q&A: Racial disparities in multiple myeloma clinical trials impact quality of results
Racial disparities continue to exist in clinical trials for patients with multiple myeloma. Along with enrollment barriers and the COVID-19 pandemic, patients with multiple myeloma face challenges for enrollment.
VIDEO: Expert discusses approvals for multiple myeloma, upcoming clinical trial data
The last year has seen important FDA approvals for the treatment of multiple myeloma and the upcoming year promises updates from ongoing clinical trials.
VIDEO: Multiple myeloma highlights from ASH 2023
In this video, Samer Al Hadidi, MD, MS (CRDSA), FACP, of Winthrop P. Rockefeller Cancer Institute at University of Arkansas for Medical Sciences, discussed multiple myeloma presentations from ASH Annual Meeting and Exposition.
Q&A: COVID-19 continues to affect multiple myeloma care, patients
Despite widespread vaccinations and preventive measures in place, the continued circulation of the COVID-19 virus remains a challenge for clinicians and patients affected by multiple myeloma.
FDA approves Tecvayli for advanced multiple myeloma
The FDA granted accelerated approval to teclistamab-cqyv for treatment of certain patients of myeloma.
Workers exposed to World Trade Center site at greater risk for myeloma precursor disease
Emergency response and recovery workers, law enforcement and construction workers who reported to the World Trade Center site after 9/11 had a twofold higher risk for myeloma precursor disease compared with the general population.
Scale may help ‘quickly identify’ high-risk medications for older adults with blood cancer
Gerontology researchers and hematologic oncology investigators from Brigham and Women’s Hospital and Dana-Farber Cancer Institute have devised a scale for assessing high-risk medications in older patients with blood cancers.
Immunotherapy a ‘significant improvement’ for treatment of multiple myeloma
Despite being behind the curve for adoption of immunotherapy, the field of multiple myeloma has witnessed monumental advances in patient survival with the use of novel agents, according to a speaker at Chemotherapy Foundation Symposium.
CAR-T will ‘play a very important role’ in multiple myeloma treatment landscape
The FDA approval of the first ever chimeric antigen receptor T-cell therapy for multiple myeloma in 2021 laid the groundwork for others to follow.